Literature DB >> 2646650

Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.

J L Grem1, P H Fischer.   

Abstract

Although the interaction between FUra and DP in HCT 116 cells is fairly complex, data from other investigators indicate that in cell lines in which inhibition of TS is growth limiting at relatively low concentrations of fluoropyrimidines, DP appears to augment the cytotoxicity of FUra and FdUrd by blocking the salvage of dThd (Miller et al., 1987; Schwartz et al., 1987). The previous in vitro data regarding the ability of DP to modulate the toxicity of fluoropyrimidines was obtained in exponentially growing cells. An additional observation that warrants consideration is a report that the inhibition of nucleoside incorporation by DP changed as a function of time in culture (Zhen et al., 1986). Hepatoma 3924A cells in lag and log phase were highly sensitive to DP with IC50 values for dThd incorporation of 0.2 and 0.32 microM, respectively. In contrast, stationary phase cells were insensitive to DP (IC50 = 38.9 microM). Amphotericin B, an antifungal agent which perturbs cell membranes, restored the sensitivity to DP in stationary cells. Several investigators have presented information on the effect of DP on fluoropyrimidines in normal tissues. Lee and Park (1987) examined the effect of DP on FUra and MTX toxicity in a soft-agar cloning assay against two human cancer cell lines and on pooled normal human bone marrow (CFU-C). DP (1 microM) potentiated the action of both MTX (0.1 microM) and FUra (5 microM) on Hep-2 (epidermoid carcinoma), MCF-7 (breast carcinoma) and CFU-C in medium supplemented with either non-dialyzed or dialyzed serum. Woodcock et al. (1987) incubated gallbladder mucosa, obtained from patients undergoing elective surgery for cholelithiasis, with control medium or varying concentrations of DP for 1 hr, and then exposed the mucosal cells to 2.5 microCi [3H]-FdUrd (2.5 microM). After 1 hr, the uptake of FdUrd into the tissue was inhibited to 49% and 42% of control by 0.1 microM and 1 microM, respectively.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646650     DOI: 10.1016/0163-7258(89)90084-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  12 in total

Review 1.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

2.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

Authors:  J R Patton
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

3.  5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.

Authors:  Y Maehara; Y Sakaguchi; I Takahashi; M Yoshida; H Kusumoto; H Masuda; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects.

Authors:  C W Hendrix; C Flexner; J Szebeni; S Kuwahara; S Pennypacker; J N Weinstein; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

Authors:  N J Curtin; K J Bowman; R N Turner; B Huang; P J Loughlin; A H Calvert; B T Golding; R J Griffin; D R Newell
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 6.  Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.

Authors:  A R Kinsella; D Smith; M Pickard
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells.

Authors:  Xiao Wu; Meng-Yao Wu; Min Jiang; Qiaoming Zhi; Xiaojie Bian; Meng-Dan Xu; Fei-Ran Gong; Juan Hou; Min Tao; Liu-Mei Shou; Weiming Duan; Kai Chen; Meng Shen; Wei Li
Journal:  Cancer Cell Int       Date:  2017-01-23       Impact factor: 5.722

8.  Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

Authors:  Ana de la Cueva; Ana Ramírez de Molina; Néstor Alvarez-Ayerza; Ma Angeles Ramos; Arancha Cebrián; Teresa Gómez Del Pulgar; Juan Carlos Lacal
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

9.  Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.

Authors:  J Pressacco; J S Wiley; G P Jamieson; C Erlichman; D W Hedley
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

10.  5-fu metabolism in cancer and orally-administrable 5-fu drugs.

Authors:  Koh Miura; Makoto Kinouchi; Kazuyuki Ishida; Wataru Fujibuchi; Takeshi Naitoh; Hitoshi Ogawa; Toshinori Ando; Nobuki Yazaki; Kazuhiro Watanabe; Sho Haneda; Chikashi Shibata; Iwao Sasaki
Journal:  Cancers (Basel)       Date:  2010-09-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.